Key result
Natural products show preclinical cardioprotection against doxorubicin toxicity, but poor bioavailability limits clinical translation.
Why the study?
Preclinical studies show natural products may protect against doxorubicin-induced cardiotoxicity, but these have not yet translated to clinical use partly due to inadequate human bioavailability.
Do natural products prevent anthracycline-induced cardiotoxicity in patients receiving doxorubicin?
Do natural products prevent anthracycline-induced cardiotoxicity in patients receiving doxorubicin?
While natural products show theoretical and preclinical promise in preventing anthracycline-induced cardiotoxicity, clinical application is currently limited by poor bioavailability.
Should not change clinical practice for doxorubicin cardiotoxicity; leaves open need for bioavailability-enhanced formulations and human trials.
Doxorubicin (DOX) is an anthracycline anticancer agent that is highly effective in the treatment of solid tumors. Given the multiplicity of mechanisms involved in doxorubicin-induced cardiotoxicity, it is difficult to identify a precise molecular target for toxicity. The findings of a literature review suggest that natural products may offer cardioprotective benefits against doxorubicin-induced cardiotoxicity, both in vitro and in vivo. However, further confirmatory studies are required to substantiate this claim. It is of the utmost importance to direct greater attention towards the intricate signaling networks that are of paramount importance for the survival and dysfunction of cardiomyocytes. Notwithstanding encouraging progress made in preclinical studies of natural products for the prevention of DOX-induced cardiotoxicity, these have not yet been translated for clinical use. One of the most significant obstacles hindering the development of cardioprotective adjuvants based on natural products is the lack of adequate bioavailability in humans. This review presents an overview of current knowledge on doxorubicin DOX-induced cardiotoxicity, with a focus on the potential benefits of natural compounds and herbal preparations in preventing this adverse effect. As literature search engines, the browsers in the Scopus, PubMed, Web of Science databases and the ClinicalTrials.gov register were used.
No takes yet. Share an insight, caveat, or question.
Szponar et al. (2024) conducted a review in Doxorubicin-induced cardiotoxicity. Natural products was evaluated. Natural products demonstrate potential cardioprotective benefits against doxorubicin-induced cardiotoxicity in preclinical studies, but clinical translation is hindered by lack of adequate bioavailability in humans.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: